Great Lakes Advisors LLC Makes New $4.07 Million Investment in Lantheus Holdings, Inc. $LNTH

Great Lakes Advisors LLC acquired a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the second quarter, HoldingsChannel.com reports. The firm acquired 36,680 shares of the medical equipment provider’s stock, valued at approximately $4,069,000.

Other large investors have also modified their holdings of the company. Farallon Capital Management LLC increased its stake in Lantheus by 56.1% in the fourth quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock valued at $361,199,000 after purchasing an additional 1,950,252 shares during the period. Reinhart Partners LLC. boosted its stake in shares of Lantheus by 2.2% during the second quarter. Reinhart Partners LLC. now owns 1,599,379 shares of the medical equipment provider’s stock worth $177,437,000 after buying an additional 34,501 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Lantheus by 3.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,415,463 shares of the medical equipment provider’s stock worth $94,202,000 after buying an additional 44,374 shares during the last quarter. Carmignac Gestion grew its holdings in shares of Lantheus by 18.4% during the first quarter. Carmignac Gestion now owns 1,328,000 shares of the medical equipment provider’s stock worth $100,729,000 after buying an additional 206,000 shares during the last quarter. Finally, Norges Bank acquired a new position in Lantheus in the 4th quarter valued at about $76,197,000. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus Trading Down 0.2%

NASDAQ:LNTH opened at $100.24 on Friday. Lantheus Holdings, Inc. has a 1 year low of $49.67 and a 1 year high of $111.86. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.89 and a current ratio of 3.06. The stock has a fifty day moving average price of $104.17 and a two-hundred day moving average price of $90.28. The stock has a market capitalization of $6.54 billion, a price-to-earnings ratio of 24.21 and a beta of -0.03.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 EPS for the quarter, topping the consensus estimate of $1.30 by $0.25. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The company had revenue of $388.18 million for the quarter, compared to analyst estimates of $363.23 million. During the same period in the previous year, the firm earned $1.57 EPS. The business’s revenue was up 2.7% on a year-over-year basis. As a group, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 4.54 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on LNTH shares. B. Riley Financial lowered Lantheus from a “buy” rating to a “hold” rating in a report on Monday. Citigroup reissued an “outperform” rating on shares of Lantheus in a research note on Friday, May 8th. The Goldman Sachs Group restated a “neutral” rating and set a $94.00 price objective on shares of Lantheus in a research report on Thursday, May 7th. Wall Street Zen downgraded shares of Lantheus from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Finally, TD Cowen lowered shares of Lantheus from a “buy” rating to a “hold” rating and dropped their price target for the stock from $110.00 to $102.50 in a research note on Monday, August 3rd. Four investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $108.11.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.